166 healthcare facilities are REMS-certified and 148 formulary approvals have been achieved through December 31, 2019, exceeding year-end goals of 125 for each metric.
Year-end 2020 goals of 465 REMS-certified facilities and 465 formulary approvals.
FY 2019 total revenues of $2.3M.
Cash and short-term investments of $66.1M as of December 31, 2019.
Department of Defense Milestone C meeting for DSUVIA is expected in Q2 2020.
Commencement of investigator-initiated studies of DSUVIA in post-operative pain management and Enhanced Recovery protocols is anticipated beginning in H1 2020.
Shares are up 4% premarket.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.